[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652722":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":25,"studyPopulation":18,"armGroups":26,"interventions":38,"overallOfficials":46,"centralContacts":54,"locations":62,"responsibleParty":83,"collaborators":18,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":18,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":18,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":18,"overallStatus":65,"whyStopped":18,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"RESnTEC, Institute of Research","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Mortality","Frequency of patients will be noted who will die within 15 days to clinical stabilization.","15 days after hospital admission",[14],{"measure":15,"description":16,"timeFrame":17},"Intermediate Syndrome (IMS)","Frequency of patients will be noted who will develop Intermediate Syndrome (IMS) within seven days of poisoning.","7 days after poisoning",null,{"allocation":20,"interventionModel":21,"interventionModelDescription":18,"primaryPurpose":22,"observationalModel":18,"timePerspective":18,"maskingInfo":23},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":24,"maskingDescription":18,"whoMasked":18},"NONE","The current standard therapy in OP is lacking in managing the Intermediate Syndrome (IMS) and the delayed complications. This deficiency underscores the need for carrying out research to test the efficacy of adjunct compounds in the better management of the toxicity of this deadly substance. MgSO4 is one of the most promising adjunctive treatments that needs to be tested. In a setting where economic instability and a compromised health system put an uneven burden on the shoulders of the patient, introducing a regimen that could possibly reduce the hospital stay and prevent the use of ventilators can be very healthy for the pockets of the government bodies as well as the patient's attendants. Assessing atropine consumption, need for mechanical ventilation, incidence of respiratory failure due to IMS, length of hospital admission, and mortality in the treatment would enable clinicians to recognize whether the adjunctive treatment is efficacious in achieving reasonable outcomes or not.",[27,34],{"label":28,"type":29,"description":30,"interventionNames":31},"Atropine plus pralidoxime with MgSO4-Group","EXPERIMENTAL","Patients will be treated with standard atropine and pralidoxime therapy along with adjunctive MgSO4 (loading dose of 4g in 100ml N\u002FS intravenous infusion over 30 minutes, followed by 1g\u002Fhr in 100ml N\u002FS continuous IV infusion for 24 hours).",[32,33],"Drug: Atropine plus pralidoxime","Drug: Atropine and pralidoxime with adjunctive MgSO4",{"label":35,"type":29,"description":36,"interventionNames":37},"Atropine plus pralidoxime-Group","Patients will be treated with standard atropine plus pralidoxime therapy alone.",[32],[39,43],{"type":40,"name":41,"description":30,"armGroupLabels":42,"otherNames":18},"DRUG","Atropine plus pralidoxime",[28,35],{"type":40,"name":44,"description":36,"armGroupLabels":45,"otherNames":18},"Atropine and pralidoxime with adjunctive MgSO4",[28],[47,51],{"name":48,"affiliation":49,"role":50},"Sana Usman","Nishtar Hospital Multan, Pakistan","PRINCIPAL_INVESTIGATOR",{"name":52,"affiliation":49,"role":53},"Arif Mahmood, FCPS","STUDY_DIRECTOR",[55,59],{"name":48,"role":56,"phone":57,"phoneExt":18,"email":58},"CONTACT","+923007154668","sunusman0@gmail.com",{"name":52,"role":56,"phone":60,"phoneExt":18,"email":61},"+923008730810","dr_arif_mahmood@yahoo.com",[63],{"facility":64,"status":65,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"Nishtar Hospital\u002FMedical University","RECRUITING","Multan","Punjab Province","60000","Pakistan","PK",{"type":72,"coordinates":73},"Point",[74,75],71.47824,30.19679,{"lat":75,"lon":74},[78,79,80,81],{"name":48,"role":56,"phone":57,"phoneExt":18,"email":58},{"name":52,"role":56,"phone":60,"phoneExt":18,"email":61},{"name":48,"role":50,"phone":18,"phoneExt":18,"email":18},{"name":82,"role":50,"phone":18,"phoneExt":18,"email":18},"Arif Mahmood",{"type":84,"investigatorFullName":85,"investigatorTitle":86,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","Muhammad Aamir Latif","Research Consultant","100652722","magnesium-sulphate-with-atropine-and-pralidoxime-vs-standard-therapy-alone-in-acute-organophosphate-poisoning-100652722",false,"NCT07777835","Magnesium Sulphate With Atropine and Pralidoxime vs Standard Therapy Alone in Acute Organophosphate Poisoning","Comparison of the Efficacy of Adjunctive Magnesium Sulphate With Standard Atropine and Pralidoxime Therapy vs Standard Therapy Alone in Acute Organophosphate Poisoning","Inclusion Criteria:\n\n* Both genders\n* Adult patients aged between 18 and 50 years\n* Confirmed clinical diagnosis of organophosphate poisoning containing insecticide, through the oral route\n* Adult patients, or their legally authorized representative, who will provide informed consent to participate in the study\n\nExclusion Criteria:\n\n* Patients with known allergy to MgSO4\n* Patients with documented pre-existing renal impairment (Serum creatinine more than 1.5mg\u002Fdl)\n* Patients with documented pre-existing cardiac impairments (e.g., heart block)\n* Pregnant or lactating women\n* Confirmed intake of any other drug or poison\n* Patients who will be declared dead on arrival or those who expired within 2 hours of presentation","ALL","18 Years","50 Years",{"count":98,"type":99},38,"ESTIMATED","INTERVENTIONAL",[102],"NA","Pakistan, being a developing country, is one of the regions with the most cases of organophosphate (OP) poisoning\u002Ftoxicity. MgSO4 is one of the most promising adjunctive treatments that needs to be tested. This study is being carried out with the objective of comparing the 15-day all-cause mortality rate and the total cumulative atropine requirement during hospitalization between patients receiving adjunctive magnesium sulphate with standard therapy and those receiving standard therapy alone.",[105],"Organophosphate Poisoning","2026-08-17",{"date":108,"type":109},"2026-08-20","ACTUAL",{"date":111,"type":109},"2026-05-10",{"date":113,"type":99},"2026-10-10",{"name":85,"class":6},1]